BridgeBio Pharma (BBIO)
74.84
-0.57 (0.76%)
Upcoming Events
Latest Headlines
BridgeBio to present infigratinib data at ESPE meeting in September
September 2, 2026 7:30 AM - StreetInsider
BridgeBio to Present New Data on the Impact of Oral Infigratinib on Medical Complications in Achondroplasia at the Annual ESPE Meeting 2026
September 2, 2026 7:30 AM - StreetInsider
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
September 2, 2026 6:55 AM - StreetInsider
BridgeBio to Participate in September Investor Conferences
September 1, 2026 7:30 AM - StreetInsider
Trump announces nine more pharma firms in drug pricing deals
August 31, 2026 3:08 PM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $110 at Mizuho
August 31, 2026 1:59 PM - StreetInsider
BridgeBio's acoramidis shows cardiac reversal data at ESC 2026
August 31, 2026 6:04 AM - StreetInsider
Acoramidis Demonstrates Reversal of Cardiac Structural Disease Progression and Functional Decline and Significantly Increases Days Alive and Free from Hospitalization in ATTR-CM
August 30, 2026 10:00 AM - StreetInsider
BridgeBio doses first patient in Phase 3b/4 acoramidis heart study
August 26, 2026 7:33 AM - StreetInsider
BridgeBio Announces First Participant Dosed in ASCEND-ATTR, a Phase 3b/4 Study Evaluating the Long-Term Effects of Acoramidis on Disease Regression in ATTR-CM
August 26, 2026 7:30 AM - StreetInsider
BridgeBio to Present New Acoramidis Data from Open-Label Extension Analyses in ATTR-CM at ESC Congress 2026
August 24, 2026 7:30 AM - StreetInsider
Form 4 BridgeBio Pharma, Inc. For: Aug 18 Filed by: Kumar Neil
August 20, 2026 4:31 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
August 19, 2026 4:34 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Aug 16 Filed by: Trimarchi Thomas
August 18, 2026 6:03 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Aug 16 Filed by: Kumar Neil
August 18, 2026 6:03 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Aug 16 Filed by: Apuli Maricel
August 18, 2026 6:02 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Kumar Neil
August 18, 2026 4:27 PM - SEC Filing
Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: KKR Genetic Disorder L.P.
August 17, 2026 5:31 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Scott Randal W.
August 17, 2026 4:33 PM - SEC Filing
Form 8-K BridgeBio Pharma, Inc. For: Aug 13
August 17, 2026 9:05 AM - SEC Filing
KKR prices secondary offering of 5 million BridgeBio shares
August 14, 2026 7:30 AM - StreetInsider
BridgeBio Pharma Announces Pricing of Oversubscribed Secondary Offering that Diversifies its Institutional Shareholder Base
August 14, 2026 7:30 AM - StreetInsider
Form 424B7 BridgeBio Pharma, Inc.
August 14, 2026 6:51 AM - SEC Filing
KKR to sell 5 million BridgeBio shares in secondary offering
August 13, 2026 5:43 PM - StreetInsider
BridgeBio Pharma Announces Launch of Secondary Offering of Common Stock on Behalf of an Existing Shareholder
August 13, 2026 5:42 PM - Globe NewsWire
BridgeBio Pharma (BBIO) PT Raised to $107 at Truist Securities
August 12, 2026 7:15 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $111 at JPMorgan
August 12, 2026 7:13 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $106 at Canaccord
August 12, 2026 6:51 AM - StreetInsider
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
August 11, 2026 4:01 PM - StreetInsider
Cantor Fitzgerald Reiterates Overweight Rating on BridgeBio Pharma (BBIO), Updates Estimates
August 11, 2026 9:44 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Lowered to $97 at Morgan Stanley
August 11, 2026 9:08 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $110 at TD Cowen
August 11, 2026 8:04 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $115 at Piper Sandler as 'Attruby Outperforms'
August 11, 2026 7:48 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $102 at Wells Fargo
August 11, 2026 6:57 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $94 at Citi
August 11, 2026 4:46 AM - StreetInsider
BridgeBio Pharma Inc. (BBIO) Misses Q2 EPS by 18c
August 10, 2026 4:33 PM - StreetInsider
Form 10-Q BridgeBio Pharma, Inc. For: Jun 30
August 10, 2026 4:32 PM - SEC Filing
Form 8-K BridgeBio Pharma, Inc. For: Aug 10
August 10, 2026 4:04 PM - SEC Filing
BridgeBio Reports Second Quarter 2026 Financial Results and Corporate Updates
August 10, 2026 4:01 PM - StreetInsider
Form 4 BridgeBio Pharma, Inc. For: Jul 30 Filed by: Apuli Maricel
August 3, 2026 4:21 PM - SEC Filing
Form SCHEDULE 13G/A BridgeBio Pharma, Inc. Filed by: FARALLON CAPITAL MANAGEMENT, L.L.C.
August 3, 2026 8:31 AM - SEC Filing
BridgeBio to Report Second Quarter 2026 Financial Results and Commercial Updates on August 10, 2026 at 4:30 pm ET
August 3, 2026 7:30 AM - StreetInsider
Form SCHEDULE 13G/A BridgeBio Pharma, Inc. Filed by: BlackRock, Inc.
July 27, 2026 4:26 PM - SEC Filing
Form S-3ASR BridgeBio Pharma, Inc.
July 24, 2026 5:20 PM - SEC Filing
Form S-8 BridgeBio Pharma, Inc.
July 24, 2026 5:17 PM - SEC Filing
H.C. Wainwright Reiterates Buy Rating on BridgeBio Pharma (BBIO)
July 24, 2026 7:26 AM - StreetInsider
Form 8-K BridgeBio Pharma, Inc. For: Jul 22
July 22, 2026 4:34 PM - SEC Filing
FDA accepts BridgeBio NDA for encaleret to treat ADH1
July 22, 2026 7:31 AM - StreetInsider
BridgeBio Announces FDA Acceptance of NDA for Encaleret for ADH1
July 22, 2026 7:30 AM - StreetInsider
BridgeBio Pharma (BBIO) PT Raised to $93 at Citi
July 16, 2026 5:03 AM - StreetInsider
Form 4 BridgeBio Pharma, Inc. For: Jul 09 Filed by: Ellis Andrea
July 13, 2026 4:42 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jul 09 Filed by: Cook Jennifer E.
July 13, 2026 4:40 PM - SEC Filing
BridgeBio Pharma (BBIO) PT Raised to $120 at H.C. Wainwright
July 13, 2026 6:38 AM - StreetInsider
Form SCHEDULE 13D/A BridgeBio Pharma, Inc. Filed by: VIKING GLOBAL INVESTORS LP
July 10, 2026 7:04 PM - SEC Filing
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
July 10, 2026 4:01 PM - Globe NewsWire
Form 144 BridgeBio Pharma, Inc. Filed by: Cook Jennifer E.
July 9, 2026 4:22 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Ellis Andrea
July 9, 2026 4:12 PM - SEC Filing
Form 8-K BridgeBio Pharma, Inc. For: Jul 01
July 2, 2026 4:24 PM - SEC Filing
BridgeBio drug shows kidney benefits in heart disease study
July 2, 2026 7:31 AM - StreetInsider
Acoramidis Associated with First-Ever Early and Sustained Direct Kidney-Protective Effects in ATTR-CM
July 2, 2026 7:30 AM - StreetInsider
BridgeBio raises $1 billion in convertible preferred equity
July 1, 2026 7:30 AM - StreetInsider
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 1, 2026 7:30 AM - Globe NewsWire
BridgeBio Raises $1 Billion in Preferred Equity to Accelerate Present and Upcoming Launches
July 1, 2026 7:30 AM - StreetInsider
BridgeBio's achondroplasia drug trial data published in NEJM
June 28, 2026 4:00 PM - StreetInsider
BridgeBio Announces Publication in the New England Journal of Medicine of Phase 3 PROPEL 3 Trial of Oral Infigratinib in Children Living with Achondroplasia
June 28, 2026 4:00 PM - StreetInsider
Form 8-K BridgeBio Pharma, Inc. For: Jun 22
June 26, 2026 8:31 AM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: Valantine Hannah
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: Lo Andrew
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: Cook Jennifer E.
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: HOMCY CHARLES J
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: AGUIAR ERIC
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: DANIELS RONALD J
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: Ellis Andrea
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: Hassan Fred
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: MOMTAZEE JAMES C
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: MCCORMICK FRANK
June 24, 2026 6:06 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: Satvat Ali J.
June 24, 2026 6:05 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 22 Filed by: Dachille Douglas A.
June 24, 2026 6:05 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Scott Randal W.
June 24, 2026 4:35 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Cook Jennifer E.
June 24, 2026 4:09 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 20 Filed by: HOMCY CHARLES J
June 23, 2026 6:46 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Cook Jennifer E.
June 23, 2026 4:34 PM - SEC Filing
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
June 23, 2026 4:31 PM - StreetInsider
Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah
June 23, 2026 4:02 PM - SEC Filing
Form 144 BridgeBio Pharma, Inc. Filed by: Valantine Hannah
June 22, 2026 4:06 PM - SEC Filing
International Regulatory Pathways Have Supported Drug Development Across Biotech and Pharma
June 22, 2026 9:05 AM - StreetInsider
BridgeBio to present Phase 3 infigratinib trial data at ICCBH 2026
June 22, 2026 7:30 AM - StreetInsider
BridgeBio to Present Primary Results from Phase 3 PROPEL 3 Trial of Oral Infigratinib for Children Living with Achondroplasia at ICCBH 2026
June 22, 2026 7:30 AM - StreetInsider
Form 4 BridgeBio Pharma, Inc. For: Jun 15 Filed by: Cook Jennifer E.
June 17, 2026 4:45 PM - SEC Filing
BridgeBio Pharma (BBIO) PT Lowered to $96 at Mizuho
June 16, 2026 6:40 AM - StreetInsider
Form 144 BridgeBio Pharma, Inc. Filed by: Cook Jennifer E.
June 15, 2026 5:35 PM - SEC Filing
Form 4 BridgeBio Pharma, Inc. For: Jun 04 Filed by: Kumar Neil
June 8, 2026 6:01 PM - SEC Filing
Mizuho on BridgeBio Pharma (BBIO): 'We believe that any such potential transient weakness could represent a potential entry point opportunity'
June 8, 2026 10:05 AM - StreetInsider
Full Article List
